.jpeg)
2026-01-26 06:00:27
Ibrutinib (generic name: Ibrutinib) is a targeted therapy prescription drug that exerts therapeutic effects by inhibiting Bruton's tyrosine kinase (BTK).
2026-01-21 02:04:41
Palisib (brand name: IBRANCE) is the world's first commercially available CDK4/6 kinase inhibitor, approved by the US FDA through the accelerated approval pathway on February 3, 2015. Developed by Pfizer, this drug is indicated for use in combination with letrozole in the treatment of postmenopausal women with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as an initial endocrine therapy regimen. Its approval is based on clinical data demonstrating a significant prolongation of progression-free survival (PFS), marking an important advancement in the treatment of hormone receptor-positive advanced breast cancer.
2026-01-19 06:07:42
Pralsetinib is a revolutionary high-selectivity RET inhibitor, precisely designed for the treatment of lung and thyroid cancers harboring RET gene mutations. With superior efficacy compared to traditional therapies and enhanced safety profile, it has delivered breakthrough survival benefits for patients with these rare mutations, establishing itself as the new standard of care.
2026-01-15 06:18:33
On October 24,2025,Syndax Pharmaceuticals announced that the U.S.Food and Drug Administration(FDA)has approved Revuforj(revumenib)for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory(R/R)acute myeloid leukemia(AML)carrying nucleolar phosphoprotein 1(NPM1)mutations and for whom there are no suitable alternative treatment options.Revuforj was previously approved in 2024 for the treatment of adult and pediatric patients aged 1 year and older with R/R acute leukemia associated with a lysine methyltransferase 2A gene(KMT2A)translocation.
